Nebivololhydrochlorid ist der arzneilich wirksame Bestandteil des Fertigarzneimittels
Nebilet® der Firma Berlin-Chemie AG, Berlin. Eine Tablette
enthält 5,45 mg Nebivololhydrochlorid, entsprechend 5 mg Nebivolol. Sonstige Bestandteile
sind Polysorbat 80, Methylhydroxypropylcellulose (E 464), Lactose-Monohydrat, Maisstärke,
Croscarmellose-Natrium, mikrokristalline Cellulose (E 460a), hochdisperses Siliciumdioxid
und Magnesiumstearat (6).
Literatur:
- Mutschler, E., Arzneimittelwirkungen. Lehrbuch der Pharmakologie und Toxikologie. 7.
Auflage Wiss. Verl.-Ges., Stuttgart 1996.
- Hochdruckliga, Behandlung des Bluthochdrucks. Empfehlungen der Hochdruchliga. MMP 21
(1998) 236 - 243.
- Nebilet®, Wissenschaftliche Monographie zum Wirkstoff
Nebivolol. Firma Berlin-Chemie AG, Berlin.
- Nebilet®, Zusatzinformation für Krankenhausapotheker. Firma
Berlin-Chemie AG, Berlin, Januar 1997.
- Janssen, P. A. J., Nevibolol. A new form of cardiovascular therapy? Drug Invest 3,
Suppl. 1 (1991) 1 - 2.
- Nebilet®, Fachinformation. Firma Berlin-Chemie AG, Berlin,
Juli 1996.
- Mc Neely, W., Goa, K. L., Nebivolol in the management of essential hypertension. Drugs
57, 4 (1999) 633 - 651.
- Janssens, W. J., et al., Animal pharmacology of nebivolol. Drug Invest. 3, Suppl. 1
(1991) 13 - 24.
- Van de Water, A., et al., Pharmacological and hemodynamic profile of nebivolol, a
chemically novel, potent, and selective b1-adrenergic antagonist. J. Cardiovasc.
Pharmacol. 11, 5 (1988) 552 - 563.
- Gao, Y., et al., Nebivolol induces endothelium-dependent relaxations of canine arteries.
Drug Invest. 3, Suppl. 1 (1991) 118 - 119.
- Cockcroft, J. R., et al., Nebivolol vasodilates human forearm vasculature: Evidence for
an L-arginine/NO-dependent mechanism. JPET 274 (1995) 1067 - 1071.
- Himmelmann, A., et al., Haemodynamic effects and pharmakokinetics of oral d- and
l-nebivolol in hypertensive patients. Eur. J. Clin. Pharmacol. 51 (1996) 259 - 265.
- Eichstädt, H., et al., Haemodynamic measurements in patients under beta-1 receptor
blocker nebivolol. Perfusion 10, 12 (1997) 449 - 454.
- De Crée, J., et al., Noninvasive cardiac haemodynamics of nebivolol. Drug Invest. 3,
Suppl. 1 (1991) 40 - 50.
- Wisenbaugh, T., et al., Long-term (3-month) effects of a new beta-blocker (nebivolol) on
cardiac performance in dilated cardiomyopathy. J. Am. Coll. Cardiol. 21, 5 (1993) 1094 -
1100.
- Van Rooy, P., De Cree, J., Haemodynamic effects of nebivolol in poor and extensive
metabolisers. Drug Invest. 3, Suppl. 1 (1991) 161 - 163.
- Van Peer, A., et al., Clincal pharmakokinetics of nebivolol : A review. Drug Invest. 3,
Suppl. 1 (1991) 25 - 30.
- Van Rooy, P., et al., Nebivolol: Blood pressure reduction in relation to b-blockade in healthy volunteers. Drug Invest. 3, Suppl. 1 (1991)
174-175.
- Fogari, R., et al., Comparative effects of nebivolol and atenolol on blood pressure and
insulin sensitivity in hypertensive subjects with type 2 diabetes. J. Human Hypertension
11 (1997) 753 - 757.
- Van Bortel, L. M. A. B., van Baak, M. A., Exercise tolerance with nebivolol and
atenolol. Cardiovasc. Drugs Ther. 6 (1992) 239 - 247.
Verantwortlich:
Zentrum für Arzneimittelinformation
und Pharmazeutische Praxis-ABDA,
Carl-Mannich-Straße 26,
65760 Eschborn
© 1999 GOVI-Verlag
E-Mail: redaktion@govi.de
